Results 71 to 80 of about 75,972 (251)

Clinical use of DNA recombinant human growth hormone

Problems of Endocrinology, 1993
The article is devoted to the issue of the clinical use of DNA recombinant human growth hormone.
openaire   +2 more sources

Herbicide Metabolic Resistance in Poaceae Plants via the GA‐GID1/DELLA‐DOF2‐P450s Module

Advanced Science, EarlyView.
Plant hormone signaling modulates herbicide resistance in Echinochloa crus‐galli. The GA–DELLA–DOF2 cascade directly activates P450 detoxification genes in two Poaceae species, uncovering a core mechanism of metabolic herbicide resistance. ABSTRACT Barnyard grass (Echinochloa crus‐galli) is one of the world's most important weeds, and the evolution of ...
Junzhi Wang, Jiale Qi, Lin Wei, Qin Yu, Zhongyuan Liu, Lianyang Bai, Lang Pan   +6 more
wiley   +1 more source

Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data

Drug Design, Development and Therapy, 2017
Juan Pedro López-Siguero,1 Roland Pfäffle,2 Philippe Chanson,3 Mieczyslaw Szalecki,4,5 Nadja Höbel,6 Markus Zabransky6 1Servicio de Endocrinología Pediátrica, Hospital Materno-Infantil, Hospital Regional Universitario de M&
López-Siguero JP, Pfäffle R, Chanson P, Szalecki M, Höbel N, Zabransky M   +5 more
doaj  

The IRE1‐XBP1s Axis Drives Inflammatory Osteolysis by Regulating a 5‐HT Dependent Endogenous Anti‐Autophagy Mechanism

Advanced Science, EarlyView.
A previously unrecognized IRE1‐XBP1s‐Slc6a4 signaling axis links endoplasmic reticulum stress to serotonin metabolism, autophagy, and inflammatory osteoclastogenesis. By promoting intracellular serotonin uptake and reducing endogenous 3‐methyladenine accumulation, this pathway accelerates inflammatory bone destruction and provides a promising ...
Pengchao Yang, Binxiang Zhu, Yuzhi He, Yang Tian, Honglei Kang, Shian Hu, Pengju Wang, Yong Xu, Zhuowei Lei, Peijun Qi, Hao Yang, Yang Lin, Yimin Dong, Feng Li, Hanfeng Guan   +14 more
wiley   +1 more source

YAP1‐Driven Pathogenic Fibro‐Adipogenic Progenitors Secrete IL‐6 and FGF21 to Mediate Muscle‐Bone Crosstalk and Promote Bone Loss

Advanced Science, EarlyView.
Fibro‐adipogenic progenitors (FAPs) in atrophic muscle undergo YAP1‐driven pathogenic activation, secreting IL‐6 and FGF21 as bone‐catabolic myokines that mediate muscle‐bone crosstalk and promote bone loss. Genetic or pharmacological targeting of this YAP1‐FAP‐myokine axis rescues skeletal deterioration, identifying FAP‐derived myokines as therapeutic
Xiaoyu Cai, Tao Xu, Rui Ma, Weikun Meng, Shutao Gao, Yakefu Abulizi, Alafate Kahaer, Chuanhui Xun, Maierdan Maimaiti, Rui Cao, Weidong Liang, Polati Maimaiti, Qiang Deng, Jun Sheng, Ting Wang, Mingchong Liu, Weibin Sheng   +16 more
wiley   +1 more source

Retinal and choroidal microvascular assessment of children receiving recombinant growth hormone therapy

International Journal of Retina and Vitreous
Background The purpose of this study is to evaluate the retinal and choroidal microvascular state in children with congenital isolated growth hormone deficiency (IGHD) and determine the effect of recombinant human growth hormone treatment on these ...
Ismail Omar, Yousra Samir Fadle, Noura M. Ibrahim El Bakry   +2 more
doaj   +1 more source

Miro1 Protects Against Acute Kidney Injury Through Modulating Mitochondrial Homeostasis via Interaction With Sirt6

Advanced Science, EarlyView.
Ischemia‐reperfusion reduces Sirt6 activity, thereby increasing Miro1 acetylation. Hyperacetylated Miro1 exhibits perinuclear distribution and degradation, thereby inducing mitochondrial dysfunction and promoting apoptosis in renal tubular epithelial cells. This pathway reveals a mechanistic link between Sirt6‐mediated deacetylation and Miro1 stability
Lin Wu, Qing Li, Yiyang Xu, Zitao Wang, Hua Shu, Yangfan Wu, Fang Lu, Zhimin Huang, Bo Zhang, Hongwei Liang, Changying Xing, Huijuan Mao, Yanggang Yuan   +12 more
wiley   +1 more source

Ten years of biosimilar recombinant human growth hormone in Europe

Drug Design, Development and Therapy, 2017
Paul Saenger Division of Pediatric Endocrinology, Department of Pediatrics, Winthrop University Hospital, Mineola, NY, USA Abstract: Recombinant human growth hormone (rhGH) has been in clinical use for more than 30 years.
Saenger P
doaj  

A Cell-Based Strategy for Bioactivity Determination of Long-Acting Fc-Fusion Recombinant Human Growth Hormone

Molecules, 2019
The long-acting growth hormone (LAGH) is a promising alternative biopharmaceutical to treat growth hormone (GH) deficiency in children, and it was developed using a variety of technologies by several pharmaceutical companies. Most LAGH preparations, such
Wenrong Yao, Lei Yu, Wenhong Fan, Xinchang Shi, Lan Liu, Yonghong Li, Xi Qin, Chunming Rao, Junzhi Wang   +8 more
doaj   +1 more source

Response to Recombinant Human Growth Hormone (rhGH) Therapy in Children with Growth Hormone Deficiency

Journal of the College of Physicians and Surgeons Pakistan
To determine the auxological response to recombinant human growth hormone (rhGH) therapy in children with growth hormone deficiency (GHD) presenting at the National Institute of Child Health, Karachi, Pakistan. Observational study. Place and Duration of the Study: Department of Paediatric Endocrinology, National Institute of Child Health, Karachi ...
Maira, Riaz, Mohsina Noor, Ibrahim, Versha Rani, Rai, Safia, Bibi, Zubair Ahmed, Khoso, Taj Mohammad, Laghari   +5 more
openaire   +2 more sources